A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD7442 in Healthy Japanese Participants
Latest Information Update: 08 Jun 2022
At a glance
- Drugs Cilgavimab/tixagevimab (Primary) ; Cilgavimab/tixagevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors MedImmune
Most Recent Events
- 08 Jun 2022 New trial record